Granza Bio, a therapeutic delivery platform developer based in San Francisco, CA, has raised over $7 million in seed funding. The funding round was led by Felicis and Refactor, with additional participation from Y Combinator, Metaplanet, Zeno Ventures, Ritual Capital, Pioneer Fund, Oxford Angel Fund, North South Ventures, and individual investors such as Richard Aberman, JJ Fliegelman, Eric Migicovsky, Eric Eldon, Eli Brown, Eoghan Mccabe, Benjamin Bryant, Yotam Rosenbaum, Will Olsen, and Joel Meyer.
The company plans to use the funds to expand its operations and development efforts. Granza Bio was founded in 2024 by a team of cancer and immunology researchers from the University of Oxford. It is led by CEO Dr. Ashwin Nandakumar and CSO Dr. Ashwin Jainarayanan.
The company is developing a novel delivery “shell” platform designed to direct therapeutic cargo to specific tissues. Granza Bio’s lead candidate focuses on leveraging the immune system’s “attack particles” to target diseases such as cancer, autoimmune disorders, and infections.
